Chikungunya virus infection-Pipeline Insight, 2021 | Analytical Research Cognizance

Chikungunya virus infection-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667943
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Chikungunya virus infection - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chikungunya virus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Chikungunya virus infection Understanding
Chikungunya virus infection: Overview
Chikungunya virus (CHIKV), a mosquito-transmitted alphavirus, is recurring in epidemic waves. In the past decade and a half, the disease has resurged in several countries around the globe, with outbreaks becoming increasingly severe. CHIKV is transmitted in two different cycles: urban and sylvatic. The urban cycle refers to transmission from human to mosquito to human, while sylvatic transmission is animal to mosquito to human. Current treatment focuses on lessening the severity of symptoms rather than curing the disease. Treatment primarily involves the use of antipyretics and NSAIDs.

"Chikungunya virus infection - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chikungunya virus infection pipeline landscape is provided which includes the disease overview and Chikungunya virus infection treatment guidelines. The assessment part of the report embraces, in depth Chikungunya virus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chikungunya virus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chikungunya virus infection R&D. The therapies under development are focused on novel approaches to treat/improve Chikungunya virus infection.

Chikungunya virus infection Emerging Drugs Chapters
This segment of the Chikungunya virus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chikungunya virus infection Emerging Drugs
VLA1553: Valneva
VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya. It was granted Fast Track designation by the FDA in December 2018. Valneva initiated a pivotal Phase 3 trial for VLA1553 in September 2020 for the treatment of Chikungunya virus infection.

mRNA-1944: Moderna Therapeutics
mRNA-1944 encodes a fully human IgG antibody originally isolated from B cells of a patient with a prior history of potent immunity against chikungunya infection. It is composed of two mRNAs that encode the heavy and light chains of this anti-chikungunya antibody within Moderna’s proprietary lipid nanoparticle (LNP) technology. Preclinical data published in Science Immunology have shown mRNA-1944 was well-tolerated, resulted in linear dose-dependent protein expression and provided 100% protection in animal models.
Further product details are provided in the report……..

Chikungunya virus infection: Therapeutic Assessment
This segment of the report provides insights about the different Chikungunya virus infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chikungunya virus infection
There are approx. 4+ key companies which are developing the therapies for Chikungunya virus infection. The companies which have their Chikungunya virus infection drug candidates in the most advanced stage, i.e. phase III include, Valneva.

Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Chikungunya virus infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravitreal
Subretinal
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chikungunya virus infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chikungunya virus infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chikungunya virus infection drugs.

Chikungunya virus infection Report Insights
Chikungunya virus infection Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Chikungunya virus infection Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Chikungunya virus infection drugs?
How many Chikungunya virus infection drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chikungunya virus infection?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chikungunya virus infection therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chikungunya virus infection and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Valneva
Moderna Therapeutics
Ridgeback Biotherapeutics
Themis Bioscience
Bharat Biotech
Takeda
Najit Technologies
Etubics Corporation
ValiRx

Key Products
VLA1553
mRNA-1944
Molnupiravir
Chikungunya virus vaccine
BBV 87
CHIKV – Inviragen
TAK 507
Research programme: antibody based Chikungunya therapeutics

Introduction
Executive Summary
Chikungunya virus infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chikungunya virus infection – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chikungunya virus infection companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chikungunya virus infection Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase III)
Comparative Analysis
VLA1553: Valneva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
mRNA-1944: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chikungunya virus infection Key Companies
Chikungunya virus infection Key Products
Chikungunya virus infection- Unmet Needs
Chikungunya virus infection- Market Drivers and Barriers
Chikungunya virus infection- Future Perspectives and Conclusion
Chikungunya virus infection Analyst Views
Chikungunya virus infection Key Companies
Appendix

Table 1 Total Products for Chikungunya virus infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Chikungunya virus infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products